Predictive biomarkers for low-dose IL-2 therapy efficacy in systemic lupus erythematosus: a clinical analysis
Arthritis Research & Therapy · 22.10.2024 · 26 (1)
DOI: 10.1186/s13075-024-03388-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Research & Therapy, online erschienen am 22.10.2024. Verfasst von Ruiling Feng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, 100044, China. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Interleukin-2, Biomarkers. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Beijing Science and Technology Planning Project.
Abstract (Originalsprache)
BACKGROUND: Low-dose IL-2 (Ld-IL2) has shown favorable therapeutic effects in systemic lupus erythematosus (SLE) therapy. However, previous clinical trials reported an SLE Responder Index-4 (SRI-4) response rate of 65.52%-68%, with approximately half failing to achieve the primary endpoint by week 24. Our study aims to determine the real-world use of Ld-IL2 and to identify determinants of its effectiveness in SLE. METHODS: We pooled data from 342 SLE patients undergoing sequential Ld-IL2 treatment, with 314 persisting for over 3 months were included in effectiveness and prediction analyses. All patients were categorized into responder (n = 136) and non-responder group (n = 178) according to SRI-4. Lupus Low Disease Activity State (LLDAS) was also analyzed to validate our results. RESULTS: Rash, lower complement 3 (C3), and renal involvement including urine protein, urine occult blood and urine casts emerged as prominent predictors of achieving SRI-4. Adjusting for baseline values using the ratio of change to baseline revealed significant differences in CD4 + T cell immune profiles between responders and non-responders. ROC analysis confirmed a satisfactory performance of rash, renal involvement, percentage change of CD4 + T cells, and C3 in predicting SRI-4, yielding an AUC of 0.933. LLDAS analysis showed that hematological involvements and lower CLA + Treg were potent predictive markers in LLDAS attainment. Conversely, renal involvement failed to have significant association in achieving LLDAS. The analysis of background therapy in SLE patients showed that MMF was more likely to reach the SRI-4 response with the combination of Ld-IL2. CONCLUSIONS: These findings uncovered the predictors of Ld-IL2 treatment efficacy in SLE patients and provided guidance to physicians for rational utilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, 100044, China.
- Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, 100044, China. hejing@pkuph.edu.cn.
ORCID-Profile: Jing He
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Beijing Science and Technology Planning Project
Zitieren
APA
Feng, R., Xiao, X., Huang, B., Zhang, K., Zhang, X., Li, Z., Jia, Y., & He, J. (2024). Predictive biomarkers for low-dose IL-2 therapy efficacy in systemic lupus erythematosus: a clinical analysis. Arthritis Research & Therapy, 26(1). https://doi.org/10.1186/s13075-024-03388-5
Vancouver
Feng R, Xiao X, Huang B, Zhang K, Zhang X, Li Z, et al. Predictive biomarkers for low-dose IL-2 therapy efficacy in systemic lupus erythematosus: a clinical analysis. Arthritis Research & Therapy. 2024;26(1). doi:10.1186/s13075-024-03388-5
BibTeX
@article{Feng2024,
author = {Feng, Ruiling and Xiao, Xian and Huang, Bo and Zhang, Kai and Zhang, Xia and Li, Zhanguo and Jia, Yuan and He, Jing},
title = {Predictive biomarkers for low-dose IL-2 therapy efficacy in systemic lupus erythematosus: a clinical analysis},
journal = {Arthritis Research & Therapy},
year = {2024},
volume = {26},
number = {1},
doi = {10.1186/s13075-024-03388-5}
}
EUVIMED